Clinical trial averages aren't limits. When data suggested 10 months on Enhertu for lung cancer, Loryn reached 19—proving every patient's path is unique.
Support ➡️ Giving.CU.EDU/CrackingCancer
youtu.be/7UhJ27bYr0U
Support ➡️ Giving.CU.EDU/CrackingCancer
youtu.be/7UhJ27bYr0U
1:16